JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB266302

Human HNRNPA3 knockout HEK-293T cell line

Be the first to review this product! Submit a review

|

(0 Publication)

HNRNPA3 KO cell line available to order. KO validated by. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, 0 bp deletion in exon 1 and 32 bp deletion in exon 1.

View Alternative Names

FBRNP, HNRPA3, Heterogeneous nuclear ribonucleoprotein A3

3 Images
Sanger Sequencing - Human HNRNPA3 knockout HEK-293T cell line (AB266302)
  • Sanger seq

Unknown

Sanger Sequencing - Human HNRNPA3 knockout HEK-293T cell line (AB266302)

Allele-1 : 32 bp deletion in exon1

Sanger Sequencing - Human HNRNPA3 knockout HEK-293T cell line (AB266302)
  • Sanger seq

Unknown

Sanger Sequencing - Human HNRNPA3 knockout HEK-293T cell line (AB266302)

Allele-2 : 0 bp deletion in exon 1.

Cell Culture - Human HNRNPA3 knockout HEK-293T cell line (AB266302)
  • Cell Culture

Unknown

Cell Culture - Human HNRNPA3 knockout HEK-293T cell line (AB266302)

Representative images of HNRNPA3 knockout HEK293T cells, low and high confluency examples (top left and right respectively) and wild-type HEK293T cells, low and high confluency (bottom left and right respectively) showing typical adherent, epithelial-like morphology. Images were captured at 10X magnification using a EVOS XL Core microscope.

Key facts

Cell type

HEK-293T

Species or organism

Human

Tissue

Kidney

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, 0 bp deletion in exon 1 and 32 bp deletion in exon 1

Product details

Recommended control: Human wild-type HEK293T cell line (ab255449). Please note a wild-type cell line is not automatically included with a knockout cell line order, if required please add recommended wild-type cell line at no additional cost using the code WILDTYPE-TMTK1.

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab266302-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266302 Human HNRNPA3 knockout HEK-293T cell line", "number":"AB266302-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab266302-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266302 Human HNRNPA3 knockout HEK-293T cell line", "number":"AB266302-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
HNRNPA3
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

HNRPA3 also known as heterogeneous nuclear ribonucleoprotein A3 is a protein involved in RNA-related processes. It has a molecular mass of approximately 39 kDa and shows expression in various tissues with higher expression in neuronal cells. This protein plays a significant role in RNA metabolism through RNA-binding activities. HNRPA3 participates in the processing transport and stability of mRNA molecules by interacting with other RNA-binding proteins.
Biological function summary

HNRPA3 is key in regulating RNA splicing by forming complexes with components such as hnRNPs a diverse group of RNA-binding proteins. These complexes contribute to the modification and alternative splicing of pre-mRNA which is essential for generating protein diversity. HNRPA3 stabilizes mRNA and influences the transcriptional activity impacting gene expression regulation. Its interactions ensure mRNA molecules are correctly processed and available for translation.

Pathways

HNRPA3 actively participates in the spliceosome pathway which is responsible for the splicing of pre-mRNA. Additionally it plays a role in the mRNA surveillance pathway ensuring the fidelity of RNA molecules. Through these pathways HNRPA3 collaborates with proteins such as HNRNPA1 and SRSF1 which also facilitate RNA binding and processing activities. This coordination is critical for maintaining cellular homeostasis.

HNRPA3 associates with neurodegenerative diseases and certain cancers. Aberrations in HNRPA3 function can contribute to frontotemporal lobar degeneration due to mislocalization and aggregation of its protein. In cancer altered expression or mutations in HNRPA3 can disrupt normal RNA splicing leading to tumor progression. Proteins like TDP-43 and FUS which share functional domains with HNRPA3 often interact with HNRPA3 in these pathological conditions suggesting a networked dysfunction in RNA processing mechanisms.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com